Verona Pharma PLC (VRNA) reports significant sales growth for Ohtuvayre, but faces increased expenses and competition in the COPD market.

Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales(recorded by ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled ...

Sanofi attributed its double-digit growth to growth in vaccines, particularly its latest flu jab. Another major revenue ...

Sanofi said its Opella business has been valued at around 16 billion euros (USD17.38 billion), or 14 times EBITDA in 2024 ...

The FDA has cleared the start of clinical trial testing of KT-621, an experimental oral medication for COPD and other ...

Dupixent was associated with a 30 and 34 percent reduction in the annualized rate of moderate or severe COPD exacerbations ...